Semperit increases profitability in Q1–3 and confirms outlook for 2024   EBITDA plus 12% to EUR 63.9 million, earnings after tax increase to EUR 7.1 million Free cash flow improves to EUR 22.4 million EBITDA guidance of around EUR 80 million confirmed for 2024   Vienna, November 7, 2024 – In the first three quarters of 2024, the Semperit Gro [ … ]

Semperit: Manfred Stanek appointed new CEO Vienna, 26 September 2024 – The Supervisory Board of Semperit AG Holding appointed Manfred Stanek as the new CEO of Semperit AG Holding today. He will join the Executive Board on 1March 2025 and take over the role of CEO on 1 April 2025; his mandate as a member of the Executive Board will run until 29 Fe [ … ]

Semperit increases profitability in the first half of 2024   EBITDA up 8% to EUR 47.3 million, earnings after tax more than doubled Free cash flow significantly improved to EUR 23.6 million Cost-cutting program takes effect: cost reductions of EUR 14.4 million, of which EUR 8.6 million in H1 EBITDA guidance confirmed at around EUR 80 million f [ … ]

Semperit finalizes sale of the remaining medical business Vienna, July 1, 2024 – Semperit has completed the sale of the medical business and transferred the remaining production and packaging of surgical gloves to the buyer of the entire medical business, the Southeast Asian Harps Global, as agreed. Combined under the discontinued operations “Surg [ … ]

Semperit: Executive Board Chairman Karl Haider will not extend his contract Vienna, June 10, 2024 – Karl Haider today informed the Chairman of the Supervisory Board of Semperit AG Holding that he will not be available for an extension of his Executive Board mandate, which expires on March 31, 2025. Karl Haider, who was appointed to the Executive B [ … ]

Semperit with stable revenue and 9% EBITDA increase in Q1 2024   Continued operations with revenue of EUR 176.0 million (–0.2%) and EBITDA of EUR 23.0 million (+9.4%) Cost reductions initiated in the previous year already reduced expenses by EUR 9.9 million, of which EUR 4.1 million was attributable to Q1 2024 EBITDA guidance of around EUR 80  [ … ]

Semperit strengthened for further growth after transformation year – earnings 2023 still burdened by sold medical business   Continued operations with revenue of EUR 721.1 million (–7.5%), EBITDA of EUR 71.8 million (–28.5%) and positive earnings after tax of EUR 24.9 million (–35.2%) Cost reductions with a run rate of more than EUR 10 million p [ … ]

Semperit starts its 200th anniversary year  Vienna, 25 January 2024 – The Semperit Group is celebrating its 200th anniversary in 2024. Founded in 1824, the company is taking this anniversary as an opportunity to highlight its centuries-long tradition but also its path to a successful future in a variety of ways under the motto “200 Years of Semper [ … ]